New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

BioVie Inc. (BIVI) vs TScan Therapeutics, Inc. (TCRX)

BioVie Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. BioVie Inc. and TScan Therapeutics, Inc. are of similar size ($9.8M and $9.4M). BioVie Inc. has the higher net margin (0.00% vs −2,219.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, BioVie Inc. leads on 10 and TScan Therapeutics, Inc. on 3.

Valuation

Metric BIVI TCRX Biotechnology median
P/E n/m n/m 8.49
P/S — 3.76 8.56
P/B 1.00 0.51 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.05 0.18 0.69
EV/Sales — (3.96) 8.00
Earnings yield (360.76%) (589.60%) (35.81%)
Free cash flow yield (289.42%) (572.40%) (25.41%)

Profitability

Metric BIVI TCRX Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin 0.00% (2,246.84%) 0.00%
Net margin 0.00% (2,219.19%) 0.00%
Free cash flow margin 0.00% (2,152.72%) 0.00%
Return on equity (143.66%) (126.45%) (51.58%)
Return on assets (119.34%) (57.03%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BIVI TCRX Biotechnology median
Revenue growth (TTM) — (38.43%) 7.20%
EPS growth (last fiscal year) 74.83% 12.28% 29.04%
Revenue growth, 5-year CAGR — 56.92% 9.54%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BIVI TCRX Biotechnology median
Debt to equity 0.00 0.87 0.00
Current ratio 2.40 2.03 4.79
Net debt to EBITDA 0.40 0.90 1.01

Dividend

Metric BIVI TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BIVI TCRX Biotechnology median
Market cap 9.76m 9.42m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack